AGP Picks
View all

Cloud-Clone pushes integrated diabetes research toolkit for pre-clinical studies

Nov. 16, 2026
By AI, Created 07:36 UTC, Nov 16, 2026, AGP -

Cloud-Clone Corp. is marking World Diabetes Day with a pitch for its diabetic animal models, detection assays and custom services aimed at pre-clinical metabolic research. The company says the combined workflow can help scientists study diabetes mechanisms, complications and drug candidates under one quality framework.

Why it matters: - Diabetes affects more than 500 million adults worldwide, and the number is projected to keep rising. - Pre-clinical diabetes research depends on animal models and validated reagents that can capture insulin resistance, beta-cell failure and complication pathways. - An integrated workflow can reduce variation, speed study timelines and support translational research from mechanism to drug screening.

What happened: - Cloud-Clone Corp. highlighted its diabetes research portfolio in a World Diabetes Day release timed to November 14. - The company is offering diabetic animal models, biomarker detection reagents and custom services for metabolic research. - The announcement frames the portfolio as an end-to-end toolkit for scientists studying diabetes and related disorders.

The details: - World Diabetes Day was co-launched in 1991 by the International Diabetes Federation and the World Health Organization to honor Frederick Banting. - The blue-circle logo represents life, health and global solidarity. - Diabetes is grouped into type 1, type 2, gestational diabetes and rarer forms. - Type 2 diabetes accounts for more than 90% of cases. - Major complications include nephropathy, retinopathy, neuropathy, diabetic foot lesions and cardiovascular events. - Core disease features include insulin resistance, progressive beta-cell dysfunction, chronic low-grade inflammation, lipid dysregulation, oxidative stress and advanced glycation end-product buildup. - Common model types include spontaneous models such as db/db mice, ob/ob mice, ZDF rats, GK rats and KK-Ay mice. - Chemically induced models include high-dose streptozotocin for type 1 diabetes studies and low-dose streptozotocin plus high-fat diet for type 2 diabetes-like glucolipotoxicity. - Diet-induced models are used to study obesity, insulin resistance and fatty-liver phenotypes. - Complication models cover nephropathy, retinopathy, peripheral neuropathy and impaired wound healing. - Comorbidity models include ApoE-knockout-based atherosclerosis, non-alcoholic fatty liver disease and osteoporosis. - Cloud-Clone says its facilities are SPF-grade and its modeling teams generate hundreds of human-disease animal models across metabolism, cardiovascular science, neuroscience and oncology. - Diabetes-focused offerings include STZ-induced diabetes, high-fat-diet-driven insulin resistance and multiple complication phenotypes. - Quality control covers blood glucose, body weight, glucose-tolerance profiles and pathological endpoints. - In-vivo services include behavioral assays, imaging, histopathology and multi-time-point tissue and biosample collection. - Histology and pathology options include H&E, Masson, Oil-Red-O, immunohistochemistry and immunofluorescence. - The reagent lineup includes ELISA kits, recombinant proteins and antibodies for human, mouse, rat and rabbit research. - Glycometabolism markers include insulin, C-peptide, glucagon, GLP-1 and proinsulin. - Insulin-resistance-related adipokines include adiponectin, leptin, resistin and visfatin. - Signaling reagents include IRS and GLUT4 antibodies for PI3K-AKT studies. - Complication markers include AGEs/RAGE, renal-function markers and lipid panels. - Inflammation and oxidative-stress panels include TNF-α, IL-6, MCP-1, SOD and MDA. - Custom services include recombinant-protein production, monoclonal and polyclonal antibody generation, ELISA and chemiluminescent kit development, and protein-antibody labeling. - The company also says the same workflow can be built around a high-fat-diet plus low-dose-STZ type 2 diabetes model, with readouts from glucose, weight and oral glucose tolerance testing. - Post-mortem studies can include Oil-Red-O staining for hepatic steatosis, Masson staining for renal fibrosis and biochemical testing of renal-function and lipid parameters. - Cloud-Clone says its products have been cited in journals including Nature and The Lancet series, with reference lists available on the company website.

Between the lines: - The release is as much a platform pitch as a product note, bundling models, assays and custom development into one research stack. - That bundled approach is designed to appeal to labs trying to move from discovery work to pre-clinical packages without stitching together multiple vendors. - The emphasis on unified quality standards points to a common pain point in translational research: inconsistent data across mixed-source materials.

What's next: - Cloud-Clone is positioning its animal models and reagents for ongoing diabetes and metabolic-disease studies worldwide. - The company is also steering researchers toward custom services that can fill gaps in assay development and antibody production. - The broader research need remains clear: better pre-clinical tools are still central to developing future diabetes therapies.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Texas Technology Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Texas Technology Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.